U.S. markets open in 2 hours 25 minutes

Revelation Biosciences, Inc. (REVB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5300+0.1600 (+11.68%)
At close: 04:00PM EDT
1.5700 +0.04 (+2.61%)
Pre-Market: 05:18AM EDT

Revelation Biosciences, Inc.

4660 La Jolla Village Drive
Suite 100
San Diego, CA 92122
United States
650 800 3717

Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Mr. James M. RolkeCEO & Director466.63kN/A1969
Mr. Chester Stanley Zygmont IIICFO & Corp. Sec.366.64kN/A1980
Ms. Sandra VedrickVP of HR & Investor RelationsN/AN/AN/A
Ms. Carol OdleSr. Director of Clinical ProjectsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Corporate Governance

Revelation Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.